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Background: Colorectal T/natural killer (NK)-cell lymphomas (TNKCL) are very rare. 
Endoscopic and clinicopathological characteristics of colorectal TNKCL have not been 
clearly demonstrated. In this study, we demonstrated the clinical characteristics of 
colorectal TNKCL. 
Methods: Endoscopic and clinicopathological characteristics were investigated in 27 
patients with colorectal monomorphic epitheliotropic intestinal T-cell lymphoma 
(MEITL), adult T-cell leukemia/lymphoma (ATLL), and other types of TNKCL. 
Results: Nine TNKCL patients (33%) were classified as MEITL, 11 (41%) as ATLL, 
and seven (26%) as other. Four patients with Epstein-Barr Virus-positive (EBV+) 
TNKCL, two indolent T-cell lymphoproliferative disorder and one anaplastic large cell 
lymphoma were included in the other group. Endoscopically, six MEITL (67%) and five 
ATLL (46%) showed diffuse-infiltrating type, in which the main endoscopic lesion was 
edematous mucosa in MEITL, while aphthoid erosion and edematous mucosa were 
typical in ATLL. Ulcerative type was identified in four other group patients (57%), 
including two EBV+ TNKCL. An increase in atypical T-intraepithelial lymphocytes (T-
IELs) was noted in seven MEITL (88%) and six ATLL (60%) patients, but not in the 
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other group (0%) patients. Five MEITL patients (56%) showed features of lymphocytic 
proctocolitis with increased CD8+ T-IELs. 
Conclusions: MEITL and ATLL occasionally invaded the colorectum, and primary 
involving MEITL was observed. Diffuse infiltrating type was the characteristic 
endoscopic finding in colorectal MEITL and ATLL, while ulcerative type was observed 
in the other group. Features of lymphocytic proctocolitis may be prodromal findings of 
MEITL. 




The gastrointestinal (GI) tract is the most involved site of extranodal non-
Hodgkin’s lymphoma, and the stomach and small intestine are the most affected organs 
[1,2]. Primary GI tract lymphomas are mainly composed of B-cell neoplasia, which 
involve the whole GI tract, including the colorectum [3]. T/natural killer (NK)-cell 
lymphoma (TNKCL) of the GI tract has occasionally been reported [4,5]. Enteropathy-
Ishibashi H, Colorectal T/NK cell lymphoma 
7 
 
associated T-cell lymphoma (EATL) frequently occurs in Europe and the United States, 
and consists of CD3+, CD30+/negative, CD56 negative lymphoma cells, which are 
closely associated with celiac disease [6]. Monomorphic epitheliotropic intestinal T-cell 
lymphoma (MEITL) mainly shows medium-sized CD8+, CD56+/negative lymphoma 
cells, and is more prevalent in East Asia, having no correlation with celiac disease [7]. 
Intestinal Epstein-Barr virus-positive (EBV+) TNKCL is mainly reported in East Asia 
and consists of CD56+/negative and CD8+/negative lymphoid cells [8,9]. Indolent T-
cell lymphoproliferative disorder (TLPD) of the GI tract mainly comprises non-
epitheliotropic CD4+ small lymphoid cells [10]. EATL, MEITL, EBV+ TNKCL and 
indolent TLPD mainly involve the small intestine, and colorectal tumor invasion has 
occasionally been reported [6-12]. Adult T-cell leukemia/lymphoma (ATLL) consists of 
CD4+ T-cell neoplasm and frequently presents leukemic changes and tumor cell 
invasion in various organs, including the GI tract [13,14]. Primary colorectal B-cell 
lymphoma is found mainly in the ileocecum and endoscopically shows predominantly 
ulcerative and polypoid types, while diffuse infiltrating type is rare [15]. Small and large 
intestinal TNKCL including colorectal MEITL and EBV+ TNKCL often presents 
ulcero-infiltrative, ulcerating, and ulcerofungating type lesions [16]. However, the 
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endoscopic and clinicopathological characteristics of colorectal TNKCL have rarely 
been reported worldwide [16,17]. 
The current study reported 27 patients with colorectal TNKCL, with MEITL and ATLL 
patients accounting for more than two-thirds of the patient population. Detailed 
endoscopic and clinicopathological characteristics were demonstrated in the TNKCL 
patients. Furthermore, features of lymphocytic proctocolitis was detected in MEITL 
patients. The relationship between lymphocytic proctocolitis and TNKCL was 
discussed.  
Methods 
Patient selection and clinical findings 
Institutional ethical approval was obtained in compliance with the Declaration of 
Helsinki (institutional review board approval number: U20-06-006). We retrospectively 
retrieved records and samples of TNKCL of the GI tract from 106 patients (32 MEITL, 
61 ATLL, 13 other types of TNKCL) taken between 1990 and 2018 at the Department 
of Pathology, Fukuoka University. Histological classification was performed according 
to the World Health Organization (WHO) classification and reference of intestinal 
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EBV+ TNKCL in 2017 [6-8, 10]. The current study focused on 27 Japanese patients 
with colorectal TNKCL. Clinical stage was determined according to the Lugano 
classification [18]. 
Endoscopic examination 
All 27 patients underwent endoscopic examination of the upper and/or lower GI tract. A 
video endoscope (Olympus Medical System, Tokyo, Japan) was used for all endoscopic 
examinations. The endoscopic images or records were reviewed retrospectively by 
experienced endoscopists (H.I, F.H). Biopsy specimens were taken from the stomach 
and/or small intestine and/or colon by standard biopsy forceps for histologic 
examination. Endoscopic findings of the main lesions of colorectal TNKCL were 
classified into three types based on a previous classification [19]: 1) diffuse infiltrating 
(colitis-like or proctocolitis-like lesion); 2) ulcerative (including stricturing and non-
stricturing); and 3) polypoid (localized) (Fig.1). 
Histology and immunohistochemistry 
Histologic examination was performed in biopsy specimens of the GI tract from all 27 
TNKCL patients and in colorectal surgical specimens from seven. In addition to the 
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cytohistological characteristics of tumors, two additional histologic findings were 
examined due to similar features between MEITL and ATLL [20]. Medium-sized and 
large atypical lymphocytes with irregular nuclei infiltrating the epithelium were defined 
as atypical intraepithelial lymphocytes (IELs). In benign-looking mucosal layers, more 
than 20 small IELs per 100 epithelial cells were considered as findings of lymphocytic 
proctocolitis. For immunohistology, monoclonal and polyclonal antibodies were applied 
to formalin-fixed tumor samples using a Leica Bond-III automated stainer (Leica 
Biosystems, Buffalo Grove, IL). Immunostaining of CD3 (PS1; Leica Biosystems, 
Newcastle, UK), CD4 (4B12; Leica Biosystems), CD8 (C81/44B, Leica Biosystems), 
CD25 (4C9; Leica Biosystems), CD56 (1B6, Leica), CD30 (BerH2, DakoCytomation, 
Glostrup, Denmark), CD194 (chemokine receptor (CCR) 4, 1G1; BD Bioscience, San 
Jose, CA), CD103 (EPR41662; Abcam, Cambridge, MA), and TIA1 (2GP; Immunotech, 
Marseille, France) was performed after antigen retrieval. Samples in which more than 
30% of the tumor cells were labeled with a particular antibody marker were classified as 
positive. Pathological findings were reviewed by two pathologists (S.N and M.T). 
Statistical analysis 
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Clinicopathological data were analyzed using the chi-squared test and Fisher’s exact 
test. A P-value of <0.05 was considered statistically significant. Overall survival (OS) 
curves of all examined patients were generated using the Kaplan–Meier method and 
analyzed by the log-rank test. 
Results 
Patient characteristics and treatments 
The clinical features of 27 patients with colorectal TNKCL are summarized in 
Table 1. Nine patients (33%) were classified as MEITL, 11 (41%) as ATLL, and seven 
(26%) as other (one EBV+ CD56+; three EBV+ CD56 negative TNKCL; two indolent 
TLPD; one anaplastic large cell lymphoma (ALCL)). The median patient age at 
diagnosis was 60 years (range, 43–84 years). One patient with MEITL and one with 
EBV+ CD56+ TNKCL each had a long history of ulcerative colitis (UC) treated with 
mesalazine, of 13 and 17 years, respectively. The most frequently encountered clinical 
symptom was chronic diarrhea in five MEITL (56%) and four ATLL (36%) patients. 
The levels of serum lactate dehydrogenase (LDH) and soluble interleukin-2 receptor 
(sIL-2R) in MEITL patients were significantly lower than those of ATLL patients 
(P<0.01). Leukemic change was frequently found in six of eight ATLL patients (75%) 
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compared with two of nine MEITL (22%) (P<0.05). Two MEITL patients (22%) and 
two of the other group (EBV+ CD56 negative TNKCL and indolent TLPD) (29%) were 
classified as stage I. One MEITL (11%) and one other group patient (indolent TLPD) 
(14%) were classified as stage II1. Six patients were considered as primary colorectal 
TNKCL without other GI tumor involvement. Four MEITL patients (44%), 10 ATLL 
(91%), and three other group patients (two EBV+ TNKCL and one ALCL) (42%) were 
classified as stage IV. Four MEITL (44%), one ATLL (9%), and two other group (both 
EBV+ CD56 negative TNKCL) (29%) patients underwent colectomy to remove the 
main tumors. Three MEITL (33%) and one ATLL (9%) patients received chemotherapy 
after surgery. Fourteen patients (52%) received combined chemotherapy. Four MEITL 
and seven ATLL patients received the CHOP regimen (cyclophosphamide, doxorubicin, 
vincristine, and prednisolone). Three MEITL patients underwent the CHASE 
(cyclophosphamide, cytarabine, etoposide, and dexamethasone) and SMILE 
(methotrexate, ifosfamide, etoposide, l-asparaginase, and dexamethasone) regimens. 
Mogamulizumab was additionally administered to two ATLL patients. Three patients 
(11%) received stem cell transplantation after chemotherapy, and three patients (11%) 
were not treated. 
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Involved GI sites and endoscopic findings of colorectal TNKCL 
Involved GI sites and endoscopic findings of the main lesions in 27 colorectal TNKCL 
patients are summarized in Table 2. Three MEITL (33%), seven ATLL (64%), and five 
other group (four EBV+ TNKCL and one indolent TLPD) (71%) patients showed 
colorectal invasion without tumor invasion into the stomach and small intestine. The 
small intestine and duodenum were the other GI-involved sites of lymphoma in six 
MEITL patients, and the small intestine, duodenum, and stomach were the involved 
sites of four ATLL. Endoscopically, six MEITL (67%), five ATLL (46%), and two other 
group (EBV+ CD56+ TNKCL and indolent TLPD) (29%) patients showed diffuse 
infiltrating type lesions, among which four MEITL patients showed edematous mucosa 
(Fig.2a, b), and three and two ATLL patients showed mainly aphthoid erosion (Fig. 2c, 
d) and edematous mucosa (Fig.2e, f), respectively. Four patients of the other group (two 
EBV+ CD56 negative TNKCL, one indolent TLPD and one ALCL) (57%), one MEITL 
(11%), and three ATLL (27%) patients showed ulcerative type lesions. Two MEITL 
(22%) and three ATLL (27%) patients showed polypoid type lesions. Seven MEITL 
patients (78%), seven ATLL (64%), and one other group (EBV+ CD56+ TNKCL, 14%) 
showed more than two colorectal lesions by lymphoma cells. Four MEITL patients 
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(44%), five ATLL (46%), and one of the other group (EBV+ CD56+ TNKCL, 14%) 
showed multiple invasions by lymphoma cells from the cecum to the rectum. 
Pathological and immunohistological findings of colorectal TNKCL 
The pathological and immunohistological findings of 27 colorectal TNKCL patients are 
summarized in Table 3. Histologically, all nine MEITL patients (100%) had 
monomorphic medium-sized cell lymphoma, while eight ATLL patients (73%) had 
pleomorphic medium-sized cell lymphoma. In the other group, one EBV+ CD56+ 
TNKCL and two indolent TLPD (42%) were composed of pleomorphic medium-sized 
cell lymphoma, and three EBV+ CD56 negative TNKCL and one ALCL (57%) showed 
monomorphic large cell lymphoma. Seven of eight MEITL patients (88%) and six of 10 
ATLL (60%) showed an increase in atypical IELs in the overlying epithelium and in 
glands in and near the tumors. These findings were not observed in other group patients 
(0%). Five MEITL patients (56%) showed features of lymphocytic proctocolitis, in 
which an increase in reactive small IELs was found in the background nonneoplastic 
mucosa (Fig. 3a, b), and one ATLL (9%) showed an increase in reactive small IELs. 
Immunohistologically, lymphoma cells in all nine MEITL patients were CD3+, CD8+, 
and TIA-1+, and eight (89%) were CD56+. Atypical and reactive IELs were CD3+, 
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CD8+, TIA-1+, and CD103+/−. Lymphoma cells in all 11 ATLL patients were CD3+, 
CD25+, and of those, nine (100%) were CD194+ (CCR4) and nine (82%) were CD4+. 
Six MEITL patients (67%), four ATLL (36%), and one other group patient (14%) 
showed CD103+ lymphoma cells. No EBERs+ tumor cells were found in MEITL and 
ATLL patients. In the other group, one patient showed nasal type EBV+ CD56+ 
TNKCL, and a further three had EBV+ CD56 negative and CD8+/negative lymphoma. 
Two indolent TLPD patients demonstrated CD4+ T-cells in the tumor, and one ALCL 
patient had CD30+, CD4+ and TIA1+ tumor cells. 
Analysis of patient prognosis 
The 50% OS of nine MEITL patients was 9.5 months, that of 11 ATLL was 9 months, 
and that of five other group patients was over 240 months. There was no prognostic 
difference in OS between MEITL and ATLL patients (Fig.4a). The 50% OS of the five 
patients (three MEITL, one EBV+ CD56 negative TNKCL and one indolent TLPD) in 
the early stages (I and II1) was more than 240 months. The 50% OS of 20 patients in the 
advanced stages (II2, IIE and IV) was 8.5 months. There was no significant difference 
between the early and advanced stages (P=0.063) (Fig.4b). 




Previous studies have shown that endoscopically, eight of 15 MEITL lesions 
(53.3%) and eight of 10 EBV+ TNKCL (80%) showed the ulcero-infiltrative type in 42 
GI TNKCL [16]. Infiltrating and superficial/erosive type lesions were rarely found in 
each of the above histological groups. Another study demonstrated that nine intestinal 
EBV+ CD56+/negative TNKCL patients showed ulcerative (n=5) and protruding (n=4) 
type lesions [8]. Furthermore, 34 of 47 EBV+ CD56+ TNKCL patients (72.3%) 
frequently showed multiple ulcerative lesions [21]. In the current study, the ulcerative 
type was frequently encountered in four of seven other group patients (57%), in which 
two EBV+ CD56 negative TNKCL were included. Six MEITL patients (67%) and five 
ATLL (46%) mainly showed the diffuse infiltrating type. Although ulcerating and 
polypoid type lesions were also found in resting MEITL and ATLL patients, the diffuse 
infiltrating type was a frequently encountered characteristic of colorectal MEITL and 
ATLL, which was different from that of EBV+ TNKCL as well as B-cell lymphoma 
[3,8,16,21]. Further detailed studies are necessary to clarify the endoscopic difference 
among MEITL, ATLL and EBV+ TNKCL. 
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Small intestinal MEITL mostly showed intramucosal spreading of lymphoma cells 
with neoplastic CD103+ and CD8+ T-IELs [11]. It was reported that lymphoma cells in 
21 of 31MEITL (68%) as well as 31 of 56 GI ATLL patients (55%) showed expression 
of CD103 homing receptor of T-IELs, and ATLL had similar histopathological 
characteristics to MEITL with respect to increased atypical and reactive T-IELs [20]. 
The endoscopic findings of MEITL have been reported as edematous mucosa with 
mosaic and diffuse mucosal thickening patterns, and shallow ulceration, as well as 
ulcerative type tumors in the small intestine [22]. The endoscopic findings of GI-
involved acute type ATLL showed superficial spreading-type lesions (equal to the 
diffuse infiltrating type) in 12 of 23 lesions (52%) [23]. In the current study, more than 
two colorectal lymphomatous lesions were frequently found in MEITL (78%) and ATLL 
(64%) patients. Histologically, increased atypical T-IELs were found in MEITL (88%) 
and ATLL (60%) patients. Although MEITL and GI ATLL showed distinct disease 
entities, the endoscopic and pathological characteristics of colorectal MEITL were 
similar to those of ATLL. 
A multicenter study from the Asia Lymphoma Study Group identified 38 MEITL 
patients, and the involved sites were the small intestine and stomach (5%), small 
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intestine (63%), small and large intestine (16%), and large intestine (18%) [11]. MEITL 
can discontinuously expand into the mucosa along the entire GI tract. Aoyama et al. 
reported a primary colonic MEITL patient with Lugano clinical stage I, having mucosal 
edema and multiple ulcers in the transverse, splenic flexure, and sigmoid colon [24]. 
The current study also demonstrated that three MEITL patients (33%) had primarily 
presenting colorectal lesions. Endoscopically, six MEITL patients (67%) showed diffuse 
infiltrating type with more than two lymphomatous lesions in the whole colorectum. A 
previous study reported two colonic MEITL patients with clinicopathological features 
that mimicked those of ulcerative colitis and lymphocytic colitis, and the latter had a 
history of 'lymphocytic colitis' 6 months before [25]. Although collagenous sprue, 
microscopic (lymphocytic and collagenous) colitis, and celiac disease show distinct 
clinical entities, these diseases reveal similar features of colitis with an increase in T-
IELs [26,27]. Five examined MEITL patients (56%) had features of lymphocytic 
proctocolitis with reactive small T-IELs, and the findings were almost similar to 
lymphocytic colitis, in which more than 20 IELs per 100 epithelial cells and no or few 
distorted crypts were detected [28]. The features of lymphocytic proctocolitis may be 
characteristic of background mucosa in colorectal and other GI MEITL. Cumulative 
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studies are necessary to clarify the relationship between lymphocytic proctocolitis and 
MEITL. 
The prognosis of GI TNKCL patients is worse, and 1- and 3-year OS rates were 
57% and 26%, respectively, in 42 intestinal MEITL patients [29]. Among them, OS of 
MEITL patients with Lugano clinical stages I, II1, and II2 was 18.8 months, which was 
significantly better than 4.9 months in stages IIE and IV (P=0.01). The Lugano stage as 
well as the performance scales were important prognostic factors. Clinical stages in 55 
GI EBV+ TNKCL patients and 61 GI-involved ATLL were also indicated as a 
significant prognostic factor (P<0.001 and P=0.017, respectively) [9,23]. In the current 
study, only six of 27 colorectal TNKCL patients (22%) were found with stage I and II1 
disease, and the 50% OS of the five was more than 240 months. The major symptom of 
examined colorectal TNKCL patients was chronic diarrhea. Thus, the clinical symptoms 
as well as the features of lymphocytic proctocolitis with CD8+ T-IELs may be important 
in detecting the early stages of colorectal TNKCL. 
Conclusions 
MEITL, ATLL and other types of TNKCL occasionally involved the colorectal 
regions, and primary and concurrently involved colorectal MEITL was recognized. The 
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endoscopic and clinicopathological characteristics of colorectal MEITL and ATLL 
revealed diffuse infiltrating lesions with increased atypical T-IELs. However, features of 
lymphocytic proctocolitis in the background mucosa were characteristic of colorectal 
MEITL. Primary colorectal MEITL patients in the early clinical stages were rarely 
identified and showed a rather prolonged clinical course. It is important to recognize 
endoscopic and clinicopathological characteristics including features of lymphocytic 
proctocolitis to detect early-stage colorectal TNKCL. 
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Figure 1. Endoscopic findings of patients with colorectal TNKCL. Low GI endoscopic 
views of the colon showing (a) diffuse infiltrating type MEITL, ulcerative type (b) 
ATLL and (c) EBV+ CD56 negative TNKCL, and (d) polypoid type ATLL. 
Figure 2. Endoscopic and histologic findings of diffusely infiltrating type MEITL (a, b) 
and ATLL (c-f). (a) Endoscopic view of sigmoid colon showing mild edematous mucosa 
with small erosion. (b) Histological analysis showing small nests of atypical 
intraepithelial lymphocytes (IELs), preserved glands, and invasion by medium-sized 
atypical lymphocytes (hematoxylin and eosin stain, ×400). (c) Endoscopic view of 
cecum showing many aphthoid colitis-like lesions. (d) Histological analysis showing 
preserved glands, small nests of atypical IELs, and invasion by pleomorphic medium-
sized atypical lymphocytes, ×400. (e) Endoscopic view of the descending colon 
showing reddish, mildly edematous mucosa. (f) Histological analysis showing invasion 
by small and medium-sized atypical lymphocytes, ×400. 
Figure 3. Lower GI endoscopic and histologic findings of features of lymphocytic 
colitis in MEITL. (a) Endoscopic view of the descending colon showing mild 
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edematous mucosa. (b) Histological analysis showing many scattered small IELs and no 
overt stromal invasion by lymphoma cells (hematoxylin and eosin stain, ×200). 
Figure 4. Overall survival (OS) curves in 25 patients with colorectal TNKCL. (a) 50% 
OS rates of MEITL, ATLL and other group were 9.5 months, 9 months, and more than 
240 months, respectively. There was no statistical difference between MEITL and 
ATLL. (b) The 50% OS of five patients with primary colorectal TNKCL in early stages 
(I or II1) was over 240 months, and that of 20 patients in advanced stages was 8.5 





















Table 1. Clinical findings and treatments of 27 colorectal T/NK cell lymphoma patients
Clinical subtype MEITL ATLL Other group Total
No. of cases 9 (33%) 11 (41%) 7 (26%) 27
Median age (range), y 63 (47–84) 64 (50–74) 54 (43–69) 60 (43–84)
Male: female 6:3 7:4 6:1 19:8
Past history of UC 1 (11%) 0 1 (14%) 2 (7%)
Chronic diarrhea 5 (56%) 4 (36%) 2 (29%) 11 (41%)
Abdominal pain 4 (44%) 3 (27%) 4 (57%) 11 (41%)
Weight loss 4 (44%) 2 (18%) 0 6 (22%)
Fever 0 2 (18%) 2 (29%) 4 (15%)
Total protein (g/dl) 5.7 (4–6.6) 6.3 (5.4–7.2) 7.5 (5.9–8.4) 6.5 (4–8.4)
Albumin (g/dl) 3.1 (2.1–3.8) 3.4 (2.6–4) 3.9 (2.7–4.4) 3.5 (2.1–4.4)
LDH (U/l) 191 (112–288)
*
785 (262–2192)
* 184 (123–244) 387 (112–2192)
sIL-2R (U/ml) 1815 (587–4410)
*
51643 (3501–154246)
* 10993 (1330–25818) 21484 (587–154246)
Leukemic change 2 (22%)
**
6/8 (75%)
** 1 (14%) 9/21 (43%)
Clinical stage I 2 (22%) 0 2 (29%) 4 (15%)
II (II1, II2, IIE) 3 (33%) 1 (9%) 2 (29%) 6 (22%)
   II1 1 (11%) 0 1 (14%) 2 (7%)
   II2 1 (11%) 0 0 1 (4%)




** 3 (42%) 17 (63%)
Surgery 1 (11%) 0 2 (29%) 3 (11%)




** 3 (42%) 14 (52%)
Chemotherapy and SCT 2 (22%) 1 (9%) 0 3 (11%)
No treatment 1 (11%) 0 2 (29%) 3 (11%)
* 
P <0.01;
 ** P <0.05; UC Ulcerative colitis; LDH Lactate dehydrogenase; sIL-2R Soluble interleukin-2 receptor
SCT, stem cell transplantation












Table 2. Involved gastrointestinal sites and endoscopic findings in 27 colorectal T/NK cell lymphoma patients
MEITL (n=9) ATLL (n=11) Other group (n=7) Total  (n=27)
Gastrointestinal sites
Colon 3 (33%) 7 (64%) 5 (71%) 15 (56%)
Colon+other 6 (67%) 4 (36%) 2 (29%) 12 (44%)
  Colon+small intestine 2 (22%) 1 (9%) 0 3 (11%)
  Colon+small intestine+duodenum 4 (44%) 0 0 4 (15%)
  Colon+duodenum+stomach 0 2 (18%) 1 (14%) 3 (11%)
  Colon+stomach 0 1 (9%) 1 (14%) 2 (7%)
Endoscopic findings
Diffuse-infiltrating 6 (67%) 5 (46%) 2 (29%) 13 (48%)
Ulcerative 1 (11%) 3 (27%) 4 (57%) 8 (30%)
Polypoid 2 (22%) 3 (27%) 1 (14%) 6 (22%)
Involved colon sites
C/A/T/D/S/R 5/6/5/4/6/6 6/7/8/6/6/6 1/4/2/1/2/2 12/17/15/11/14/14
Localized lesion 2 (22%) 4 (36%) 6 (86%) 12 (44%)
Multiple lesions 7 (78%) 7 (64%) 1 (14%) 15 (56%)
  Two lesions 3 (33%) 1 (9%) 0 4 (15%)
  Three lesions (T+D+R) 0 1 (9%) 0 1 (4%)
  Six lesions (C+A+T+D+S+R) 4 (44%) 5 (46%) 1 (14%) 10 (37%)
C Cecum; A Ascending colon; T Transverse colon; D Descending colon; S Sigmoid colon; R Rectum












Table 3. Pathological and immunohistological findings of 27 colorectal T/NK cell lymphoma patients
MEITL (n=9) ATLL (n=11) Other group (n=7) Total (n=27)
Histological findings
  Monomorphic medium-sized cell 9 (100%)
*
1 (9%)
* 0 (0%) 10 (37%)
  Pleomorphic medium-sized cell 0 (0%)
*
8 (73%)
* 3 (42%) 11 (41%)
  Monomorphic large cell 0 (0%) 0 (0%) 4 (57%) 4 (15%)
  Pleomorphic large cell 0 (0%) 2 (18%) 0 (0%) 2 (7%)
Increased atypical IELs in tumors 7/8 (88%) 6/10 (60%) 0/5 (0%) 13/23 (57%)
Lymphocytic proctocolitis 5 (56%)
**
1 (9%)
** 0 (0%) 6 (22%)
Tumor cell markers
















* 1 (14%) 10 (37%)
CD30 0/8 (0%) 2/9 (22%) 4 (57%) 6/24 (25%)
CD194 (CCR4) 0/7 (0%)
*
9/9 (100%)
* 0 (0%) 9/23 (39%)




* 6 (86%) 15/24 (63%)




P <0.05; IELs Intraepithelial lymphocytes
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